The anticipation surrounding dose optimization data for Pfizer (NYSE:PFE)'s obesity treatment, danuglipron, was also mentioned as a point of interest for the first quarter. However, the analyst ...
New data showed that prior malignancy may influence survival outcomes in patients with metastatic colorectal cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback